Specifically, TP53 mutation, which occurs in 5–20% of cases [1,17,18], is the most impactful negative prognostic marker in patients with MCL, regardless of age, MIPI, delivered therapy, or morphology [17,19]. The gene discussed is TP53; the disease is mantle cell lymphoma.